PPCH 12-2 Minor Tracked Changes

Tuesday through Wednesday of next week LD Micro will hold its Main Event Conference.  It is the largest independent conference for small and microcap companies.  What really separates the conference is the influential buy-side and sell-side players that show up.  Not to downplay the importance of other Micro-Cap conferences, but this one can truly have a huge effect on the presenting companies and their market.

One company we have our eye on that will be presenting is Propanc Health Group Corporation (PPCH)PPCH is an emerging healthcare company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers.

Company CEO James Nathanielsz, will be presenting is presenting Wednesday, December 7th at 1 PM PST / 4 PM EST.

The company will have quite a bit to talk about including the data from the GLP (Good Laboratory Practice) compliant, 28 day repeat dose toxicokinetic study on their PRP treatment which will form the basis of a clinical trial application in the UK. The purpose of the study was to evaluate the toxicokinetic parameters of PRP following repeated, daily intravenous tail vein administration in rats and to evaluate distribution and bioavailability of the test articles over an extended period.

The company is seeking indications in both pancreatic and ovarian cancers.

PPCH is on filed a second orphan medicinal product designation (OMPD) application for ovarian cancer with the European Medicines Agency (EMA) this month. Orphan drug designation applications will also be filed for pancreatic and ovarian cancers with the U. S. Food and Drug Administration (FDA) in the near future.

This company has made major progress over the past year and a half, and investors learning about the company’s potential at this price range will likely be excited to grab this bottom.  This stock should push to a much higher valuation as more positive news rolls in.

Stellar Biotechnologies, Inc. (SBOT) is another strong biotech presenting at the LD Micro conference next week.  The company will provide a review of its Stellar KLH™ business and recent corporate activities.

MannKind Corporation (MNKD) is benefitting from the old “rising tides lifts all boats” paradigm.  The stock is in the Biomedical and Genetics industry, an industry which is seeing solid revenue revisions as of late.  MNKD is one of many beneficiaries of this bullish sentiment on the sector.

Heat Biologics, Inc. (HTBX) after being beat up a bit on bad results from their bladder cancer indication drug HS-410, the stock is rebounding a bit as some investors feel the stock is oversold, since the drug is not exactly a failure yet.

CTI Biopharma Corp. (CTIC) just announced the results of a translational pharmacology study comparing biomarker activity profiles for three JAK inhibitors: pacritinib, ruxolitinib and momelotinib, using the BioMAP® Diversity PLUS panel of in vitro human primary cell-based systems. The results demonstrated distinct profiles amongst these JAK inhibitors and suggest that clinical responses are likely to be distinct with each agent. The results were presented at the EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium, November 29 – December 2 in Munich, Germany.

Arrowhead Pharmaceuticals, Inc. (ARWR) has recently halted 3 of their drugs.  The stock has taken a beating recently, but might be turning around here.  It is worth keeping an eye on.

But if there is one stock on this list you pay attention to, Propanc Health Group, tops the list.  This past winner is set up for a major bullish run.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC. which owns Microcapspeculators.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC. which owns, Microcapspeculators.com may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC. which owns Microcapspeculators.com may be compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. For Full Legal Disclaimer Click Here.

Distributed by In2town Public Relations

Media Contact
Company Name: Microcap Speculators
Contact Person: Media Manager
Email: info@microcapspecualtors.com
Phone: 1-702-720-6310
Country: United States
Website: http://microcapspeculators.com/